Delmaine Donson
- Repare Therapeutics (NASDAQ:RPTX) said it received ~$1.5M (¥200M) research service payment from Japan's Ono Pharmaceutical (OTCPK:OPHLF) (OTCPK:OPHLY).
- The payment was due to achievement of a research trigger, under the companies' 2019 strategic partnership agreement.
- Under the terms agreement, Repare is mainly responsible for carrying out research activities for its Polθ program, now known as RP-2119, until the first submission of an IND in the U.S. or Japan, the company added.
- "This reflects an important milestone in our RP-2119 Polθ program, as we undertake our IND-enabling studies and prepare for our previously guided initiation of clinical trials in the summer of 2023," said Repare's Chief Business Officer Kim Seth.